J&J Told to Pay $300 Million More by Talc-Cancer Jury
(Bloomberg) -- Johnson & Johnson was ordered by a jury to pay $300 million in punitive damages to a woman who blamed her rare asbestos-related cancer on decades of daily use of the company's talc-based products.
The ruling brings to $325 million the amount the state-court jury in Manhattan said J&J should pay Donna Olson and her husband over her cancer that she blamed on J&J's baby powder and its former Shower-to-Shower product.
The total verdict is one of the highest in more than two years of litigation over J&J talc products.
Kim Montagnino, a J&J spokeswoman, said the company would appeal the jury's findings because it believes the trial was flawed. “Of all the verdicts against Johnson & Johnson that have been through the appellate process, every one has been overturned,” she said in an emailed statement.
J&J faces more than 14,000 claims that its powders caused ovarian cancer and mesothelioma, a rare cancer linked to asbestos exposure. The company denies its products ever contained the carcinogen and argues talc doesn't cause the life-threatening illnesses. Olson has mesothelioma in her lungs, according to court filings.
“With this verdict, yet another jury has rejected J&J's misleading claims that its talc was free of asbestos,” Jerome Block, the couple's lawyer said in an emailed statement. “The internal J&J documents that the jury saw, once more laid bare the shocking truth of decades of cover-up, deception and concealment by J&J of the asbestos found in talc baby powder.”
The case is Olson v. Brenntag, No. 190328/2017, New York Supreme Court (Manhattan).
To contact the reporters on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.net;Margaret Cronin Fisk in Detroit at mcfisk@bloomberg.net
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Joe Schneider
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.